Novomer Inc., a materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide, today announced that it has raised $14 million in a Series B funding.

First Demonstration of Clinical Efficacy for Novel Class of Resolvin Therapeutics

Enables Breakthrough in vivo Imaging Analysis of Established Apoptosis and Cell Death Biomarkers in Research and Drug Development

CAMBRIDGE, MA – September 2, 2009 – Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company’s Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas Naclerio, Ph.D., who will continue serving as Chairman of the Board.

Achieves Significant Commercial and Technical Milestones

Engages Thomas Weisel Partners to Advise on Strategic Alternatives

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its operating highlights for the quarter ended June 30, 2009 and other recent developments following the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2009.

Single Molecule Sequencing Technology Will Play Integral Role in Japan's National Sequencing Center

CAMBRIDGE, Mass. – September 10, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean body mass and muscle volume. The results from this randomized, placebo-controlled study were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland

Phase I Results Presented at American College of Clinical Pharmacology

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing. New investor Panorama Capital led the financing round, joining founding investors InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain new and existing investors, including Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures (the “Existing Investors”) and Ron Lowy, the Company’s chief executive officer, to raise approximately $10 million in gross proceeds in a private placement through the s